利图西马布与葡萄糖皮质激素结合治疗脏综合征的有效性以及对功能,凝血功能和炎症反应的影响
概括
这项研究表明,Rituximab与葡萄糖皮质激素治疗相结合显著改善脏功能和凝在患有脏综合征的患者,同时也减少炎症标志物.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脏综合征是一种复杂的脏疾病.
- 葡萄糖皮质类药物是标准的治疗方法,但需要新的治疗方法.
- 利图西马布提供了向免疫调节的选择.
研究的目的:
- 为了评估Rituximab加上葡萄糖皮质激素在性综合征中的疗效.
- 评估联合治疗对功能的影响.
- 为了研究对凝血和炎症标志物的影响.
主要方法:
- 一项观察性研究涉及60名肺综合征患者.
- 患者被分为对照组 (葡萄糖皮质激素) 和观察组 (利图西马布+葡萄糖皮质激素).
- 治疗持续时间为6个月.
主要成果:
- 观察组显示出更高的总有效率和血清白蛋白增加.
- 观察到血清肌素和24小时尿蛋白的显著降低.
- 凝血标记物 (纤维原,D-二次体) 和炎症标记物 (CRP,IL,TNF-α) 显著下降.
结论:
- 与葡萄糖皮质类药物结合的瑞图西马布对脏病综合征有效.
- 这种联合治疗改善了功能和凝血.
- 治疗也有效地减少了性综合征患者的炎症反应.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Nephrotic Syndrome II : Assessment and Medical Management
24
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
24
Nephrotic Syndrome III : Nursing Management
49
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
49
Nephrotic Syndrome I : Introduction
33
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
33
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239


